1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide → HCID 86612618, Verbindung

HRID 1436140

Reaktionsgleichung

Reaktionsgleichung von HRID 1436140
CCN(C(C)C)C(C)C.CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.FC(F)(F)C(O)=O.[Cl:38][CH2:39][CH2:40][CH2:41]/[C:42](=[CH:46]\[C:47]1[CH:52]=[CH:51][C:50]([N:53]2[CH:57]=[C:56]([CH3:58])[N:55]=[CH:54]2)=[C:49]([F:59])[CH:48]=1)/[C:43]([OH:45])=O.[F:60][C:61]1[CH:66]=[C:65]([F:67])[CH:64]=[CH:63][C:62]=1[CH:68]([NH2:70])[CH3:69]>CN(C=O)C.C(OCC)(=O)C>[F:60][C:61]1[CH:66]=[C:65]([F:67])[CH:64]=[CH:63][C:62]=1[CH:68]([NH:70][C:43](=[O:45])/[C:42](=[CH:46]/[C:47]1[CH:52]=[CH:51][C:50]([N:53]2[CH:57]=[C:56]([CH3:58])[N:55]=[CH:54]2)=[C:49]([F:59])[CH:48]=1)/[CH2:41][CH2:40][CH2:39][Cl:38])[CH3:69]

Komponenten

8

Versuchsvorschrift

DIEA (0.12 mL), WSC (88 mg), and HOBT (62 mg) were added to a solution of (E)-5-chloro-2-{1-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene}valeric acid trifluoroacetate (100 mg) and 1-(2,4-difluorophenyl)ethylamine (54 mg) in DMF (5 mL) at room temperature, and the reaction solution was stirred at room temperature for one hour. Ethyl acetate was added to the reaction solution, which was then sequentially washed with saturated sodium bicarbonate water, water, a saturated ammonium chloride solution, and brine. The resulting organic layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system) to obtain 98 mg of (E)-5-chloro-2-{1-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene}valeric acid [1-(2,4-difluorophenyl)ethyl]amide. (E)-5-chloro-2-{1-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene}valeric acid [1-(2,4-difluorophenyl)ethyl]amide (98 mg) was dissolved in DMF (3 mL). 60% sodium hydride (10 mg) was added to the reaction solution at room temperature, and the reaction solution was stirred at room temperature for 30 minutes. Saturated sodium bicarbonate water was added to the reaction solution, followed by extraction with ethyl acetate. The resulting extraction layer was dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system) to obtain 69 mg of the title compound as a racemate. The compound (20 mg) was separated by CHIRALCEL OJ-H manufactured by Daicel Chemical Industries, Ltd. (2 cm×25 cm; mobile phase: ethanol-hexane system) to obtain the title optically active compound with a retention time of 18 minutes (Example 82) (7 mg) and the title optically active compound with a retention time of 24 minutes (Example 83) (4 mg). The property values of the title compound are as follows.

Aufarbeitung

  1. washwas then sequentially washed with saturated sodium bicarbonate water, water
  2. dry with materialThe resulting organic layer was dried over magnesium sulfate
  3. concentrationconcentrated under reduced pressure
  4. customThe residue was purified by silica gel column chromatography (carrier: Chromatorex NH; elution solvent: heptane-ethyl acetate system)

Quellen und Nachweise

ORD-Eintrag
ord-3538d8e3a31a4dcf9f54523825afceab
Quelldatensatz
uspto-grants-2009_11
Patentnummer
US07618960B2

Verknüpfte Notizen

Wird geladen…